Table 3.
List of candidate drug–drug interactions (DDIs) not accepted by the expert panel
| # | Candidate drug–drug interaction pair (object–precipitant drug/class) | Status | Considerations suggested by the expert panel |
| 1 | Abatacept–tumor necrosis factor (TNF) inhibitors | Deleted | Therapeutic duplication not a DDI |
| 2 | Abatacept–interleukin-1 receptor antagonist | Deleted | Therapeutic duplication not a DDI |
| 5 | Aurothioglucose–artemether + lumefantrine (coartem) | Deleted | Coartem has off-market status |
| 7 | Febuxostat–theophylline | Deleted | Only a theoretical interaction with no corroborating evidence |
| 9 | Gemfibrozil–statins | Deleted | Delete as clinical benefit of co-prescribing outweighs risk |
| 10 | Indinavir–atazanavir | Deleted | Therapeutic duplication not a DDI |
| 12 | Linezolid–triptans | Deleted | Deleted due to low rating score by knowledge base vendors |
| 13 | Linezolid–sympathomimetic drugs | Deleted | Does not meet criteria for contraindicated DDI |
| 14 | Metformin–contrast media | Deleted | Does not meet criteria for contraindicated DDI |
| 15 | Miglitol–digestive enzymes | Deleted | Does not meet criteria for contraindicated DDI |
| 17 | Natalizumab–immunosuppressants | Deleted | Therapeutic duplication not a DDI |
| 18 | Nitrates–5 phosphodiesterase type (PDE) inhibitors | Deleted | Does not meet criteria for contraindicated DDI |
| 19 | Pentostatin–fludarabine | Deleted | Therapeutic duplication not a DDI |
| 24 | Sodium oxybate–CNS depressants | Deleted | Consider deletion since sodium oxybate is not used in routine practice |
| 26 | HMG Co-A reductase inhibitors–telithromycin | Subsumed | Merged with DDI #25 due to expansion of precipitant dose |
| 29 | Tranylcypromine–furazolidone | Deleted | Consider deletion since furazolidone is no longer available on the US market |